Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avadel Pharmaceuticals ( (AVDL) ) has provided an announcement.
Avadel Pharmaceuticals is actively engaging with the FDA as its Supplemental New Drug Application for LUMRYZ, aimed at treating cataplexy and excessive daytime sleepiness in pediatric narcolepsy patients aged 7 and older, continues to undergo review with a target action date set for September 7, 2024. The company remains dedicated to collaborating with the FDA throughout the review process.
For detailed information about AVDL stock, go to TipRanks’ Stock Analysis page.